We're Driving Expanded Access to Comprehensive Genomic Profiling

FOUNDATION MEDICINE®

Insurance Coverage

- All Foundation Medicine tests are covered by Original Medicare[1] and Medicare Advantage[2] for qualifying patients.[3,4]
- Once any applicable deductibles are met, patients with TRICARE who receive covered Foundation Medicine testing have no out-of-pocket costs.
- Cigna covers FoundationOne CDx and FoundationOne Liquid CDx in the cancer types where they have an FDA-approved companion diagnostic for qualifying beneficiaries.[5]
- 70 commercial plans cover one or more Foundation Medicine CGP tests.

Our FoundationAccess™ Program

Our experience shows that:



84%
of patients have a $0 financial responsibility
for Foundation Medicine testing[4]

Our FoundationAccess™ program supports providers and patients through the coverage and billing process.

- For each CGP test ordered we complete a benefits investigation and reach out to all patients who we expect may have out-of-pocket costs.
- We support providers and patients by helping obtain prior authorizations when required, billing the patient's health plan for the test and appealing denials with the patient's consent.
- The final cost for a patient's bill is determined after billing the health plan, and exhausting all available appeal efforts.

Financial Assistance Program

Financial assistance is available for qualifying patients who have out-of-pocket costs associated with Foundation Medicine testing. Financial assistance is based on need and can be applied for at any point during the testing process.*

* Foundation Medicine's Financial Assistance Program is only available to patients whose tests were ordered within the United States and U.S. territories.

Enhanced Prior Authorization Support

- Foundation Medicine is now offering enhanced prior authorization support, enlisting the services of third-party authorization support company Glidian.
- Glidian may be able to submit prior authorization requests to a subset of health plans and/or lab benefit management organizations, such as AIM and Beacon for UHC, that Foundation Medicine has historically been prohibited from submitting requests to.
- **To enroll visit *www.glidian.com/provider.***

Questions

The Foundation Medicine team is here to help. If you or your patient has an Explanation of Benefits (EOB) or bill in hand and have any questions, please contact our billing department.

Call: 877.246.9204

Email: foundationmedicine@mylabbill.com

Fax: 440.528.6010

To order a test, go to *www.foundationmedicine.com/order*

FoundationOne®Heme is a laboratory developed test that was developed and its performance characteristics determined by Foundation Medicine. FoundationOne Heme has not been cleared or approved by the U.S. Food and Drug Administration. For more information on FoundationOne Heme, please see its Technical Specifications at foundationmedicine.com/heme.

FoundationOne®CDx and FoundationOne®Liquid CDx are qualitative next-generation sequencing based in vitro diagnostic tests for advanced cancer patients with solid tumors and are for prescription use only. FoundationOne CDx utilizes FFPE tissue and analyzes 324 genes as well as genomic signatures. FoundationOne Liquid CDx analyzes 324 genes utilizing circulating cell-free DNA and is FDA-approved to report short variants in 311 genes. The tests are companion diagnostics to identify patients who may benefit from treatment with specific therapies in accordance with the therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the tests does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy for testing with FoundationOne CDx when archival tissue is not available which may pose a risk. Patients who are tested with FoundationOne Liquid CDx and are negative for companion diagnostic mutations should be reflexed to tumor tissue testingand mutation status confirmed using an FDA-approved tumor tissue test, if feasible. For the complete label, including companion diagnostic indications and important risk information, please visit www.F1CDxLabel.com and www.F1LCDxLabel.com.

References:

1. Medicare administered by federal government.
2. Medicare administered by private insurers.
3. For FoundationOne®CDx and FoundationOne®Liquid CDx, see "Decision for Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced cancer – CAG-00450R." (See Appendix B) available in the Medicare Coverage Database, https://www.cms.gov/medicare-coveragedatabase/new-search/search.aspx.
4. For FoundationOne®Heme, see the "Local Coverage Determination (LCD): MolDX: NEXT-GENERATION Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies (L38047) available in the Medicare Coverage Database, https://www.cms.gov/medicarecoverage-database/new-search/search.aspx
5. Cigna provides coverage for commercially insured beneficiaries, in accordance with the criteria within Cigna's Medical Policy 0520, titled "Molecular Diagnostic Testing for Hematology and Oncology Indications," in the cancer types where FoundationOne CDx and FoundationOne Liquid CDx are an FDA-approved companion diagnostic, and when prior authorization is obtained.

FOUNDATION MEDICINE®

www.foundationmedicine.com | Tel 888.988.3639 | Fax 617.418.2290 | US-PF-2000041 V3.0